JERUSALEM, Nov. 15, 2017 /PRNewswire/ — Intec Pharma LTD (NASDAQ: NTEC) (TASE: NTEC) today announced its third quarter 2017 financial results and provided a corporate update.
“The third quarter was truly transformational for Intec Pharma.Â We advanced our clinical development programs and are continuing to move forward with our pivotal Phase 3 trial in Parkinson’s Disease. Additionally, we enhanced our organizational capabilities to fully develop and commercialize the Accordion Pill, taking us another step closer to our goal of becoming a global drug delivery company. We made significant additions in Medical Affairs, Business Development and to our senior leadership team,” said Jeffrey Meckler, Chief Executive Officer of Intec Pharma. “Finally, we successfully completed a public equity offering to provide additional funding for our clinical program in Parkinson’s Disease, on-going operations and product development. We are well-positioned to advance our exciting proprietary drug delivery platform into new areas